본문 바로가기

A Tumor-Immune Interaction Model for Synergistic Combinations of Anti PD-L1 and Ionizing Irradiation Treatment

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q2
저널
PHARMACEUTICS12(9) · 2020
피인용
Web of Science 11Scopus 11
FWCI (Scopus)
0
JCR IF
JCR 2019 4.421
ISSN
1999-4923

저자

  1. 변종혁제1저자Department of Mathematics, Pusan National University, Busan, 46241, Korea;
  2. 윤인수College of Pharmacy, Pusan National University, Busan, 46241, Korea;
  3. 정용담Department of Mathematics, Pusan National University, Busan, 46241, Korea;
  4. 김성찬Department of Mathematics, Pusan National University, Busan, 46241, Korea;
  5. 정일효교신저자Department of Mathematics, Pusan National University, Busan, 46241, Korea;

초록

Combination therapy with immune checkpoint blockade and ionizing irradiation therapy (IR) generates a synergistic effect to inhibit tumor growth better than either therapy does alone. We modeled the tumor-immune interactions occurring during combined IT and IR based on the published data from Deng et al. The mathematical model considered programmed cell death protein 1 and programmed death ligand 1, to quantify data fitting and global sensitivity of critical parameters. Fitting of data from control, IR and IT samples was conducted to verify the synergistic effect of a combination therapy consisting of IR and IT. Our approach using the model showed that an increase in the expression level of PD-1 and PD-L1 was proportional to tumor growth before therapy, but not after initiating therapy. The high expression level of PD-L1 in T cells may inhibit IT efficacy. After combination therapy begins, the tumor size was also influenced by the ratio of PD-1 to PD-L1. These results highlight that the ratio of PD-1 to PD-L1 in T cells could be considered in combination therapy.

키워드

immunotherapyanti-PD-L1ionizing irradiationpharmacokineticstumor-immune interactionglobal sensitivityimmuno-oncologymathematical modelingMONOCLONAL-ANTIBODIESIMMUNOTHERAPY

식별자

Scopus EID
2-s2.0-85090522992
WoS UID
000579941800001